Angiotensin I

Base Information

• Chemical Name: Angiotensin I
• CAS No.: 484-42-4
• Molecular Formula: C62H89N17O14
• Molecular Weight: 1296.49
• DSSTox Substance ID: DTXSID80866222
• Nikkaji Number: J38.546H
• Wikidata: Q539799
• Metabolomics Workbench ID: 70072
• ChEMBL ID: CHEMBL262670
• Mol file: 484-42-4.mol

Synonyms:Angiotensin I

Chemical Property of Angiotensin I

Chemical Property:

• Refractive Index: 1.667
• PKA: 3.27±0.10(Predicted)
• PSA: 493.22000
• Density: 1.43 g/cm³
• LogP: 3.83280
• Storage Temp.: -15°C
• Solubility.: ≥129.6 mg/mL in DMSO; ≥124.2 mg/mL in H2O; ≥9.16 mg/mL in EtOH
• Water Solubility.: Soluble to 1 mg/ml in water.
• XLogP3: -1.1
• Hydrogen Bond Donor Count: 16
• Hydrogen Bond Acceptor Count: 18
• Rotatable Bond Count: 37
• Exact Mass: 1295.67749058
• Heavy Atom Count: 93
• Complexity: 2550

Purity/Quality:

97% ^*data from raw suppliers

AngiotensinI(human,mouse,rat) ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Canonical SMILES: CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC4=CN=CN4)C(=O)NC(CC(C)C)C(=O)O)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N
• Isomeric SMILES: CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N[C@@H](CC4=CN=CN4)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC5=CC=C(C=C5)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
• Uses: Angiotensin I (human) stimulates the release of aldosterone, another hormone, from the adrenal cortex. It acts as a precursor to angiotensin II. It acts as endogenous peptide substrate for angiotensin converting enzyme (ACE), precursor to the vasoconstrictor peptide angiotensin II

Technology Process of Angiotensin I

There total 8 articles about Angiotensin I which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 72.7%

→ glp-Leu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro-OH + angiotensin I (484-42-4)

Guidance literature:

Reference yield: 44.8%

→ angiotensin I (484-42-4)

Guidance literature:

Reference yield:

Fmoc-Val-OH (68858-20-8) + Fmoc-Leu-OH (35661-60-0) + N-Fmoc-Tyr-OH (112883-29-1,92954-90-0) + Fmoc-Pro-OH (71989-31-6) + N-Fmoc L-Phe (35661-40-6) + N-α-9-fluorenylmethoxycarbonyl-aspartic acid (136083-57-3,136083-73-3,119062-05-4) + Fmoc-Ile-OH (71989-23-6,251316-98-0) + Fmoc-L-Arg-OH (91000-69-0,130752-32-8) + (9-fluorenylmethoxycarbonyl)-L-histidine (116611-64-4) → angiotensin I (484-42-4)

Guidance literature:

Fmoc-Leu-OH; With 4-methyl-morpholine; 1-hydroxy-7-aza-benzotriazole; 6-chloro-3-((dimethylamino)(dimethyliminio)methyl)-1H-benzo[d][1,2,3]triazol-3-ium-1-olatehexafluorophosphate(V); In 1-methyl-pyrrolidin-2-one; N,N-dimethyl-formamide; at 20 ℃; for 0.25h; Rink-Amide Tentagel resin

With piperidine; In N,N-dimethyl-formamide; Rink-Amide Tentagel resin

Fmoc-Val-OH; N-Fmoc-Tyr-OH; Fmoc-Pro-OH; N-Fmoc L-Phe; N-α-9-fluorenylmethoxycarbonyl-aspartic acid; Fmoc-Ile-OH; Fmoc-L-Arg-OH; (9-fluorenylmethoxycarbonyl)-L-histidine; Further stages;

upstream raw materials:

1-(tert-butoxycarbonyl)-L-proline

t-Boc-L-valine

N-(tert-butyloxycarbonyl)-L-isoleucine

N-tert-butoxycarbonyl-L-phenylalanine

Downstream raw materials:

L-valine

L-Aspartic acid

L-arginine

L-leucine

Refernces

Substrate specificity and inhibition of human kallikrein-related peptidase 3 (KLK3 or PSA) activated with sodium citrate and glycosaminoglycans

10.1016/j.abb.2010.03.022

The research presents an in-depth study on the enzymatic properties and substrate specificity of human recombinant kallikrein-related peptidase 3 (KLK3), also known as prostate-specific antigen (PSA), in the presence of glycosaminoglycans (GAGs) and sodium citrate. The experiments involved the use of various substrates, including fluorescence resonance energy transfer (FRET) peptides and angiotensin I, to assess the hydrolytic efficiency of KLK3. The study utilized recombinant KLK3 expressed in an insect/baculovirus system and employed techniques such as heparin–Sepharose affinity chromatography, radioimmunoassay, and spectrofluorimetry to evaluate the effects of sodium citrate and GAGs on KLK3's conformation and activity. The analyses included kinetic measurements, pH profiling, and inhibition assays with compounds like Z-Pro-Prolinal and ortho-phenantroline, providing insights into the enzyme's activation, specificity, and potential for inhibitor design.